Abstract
Background: New insights on the relationship between weight loss and hypertension and the role of the newly approved anti-obesity drugs on hypertension will be discussed
Methods: Weight loss is a major factor to reduce blood pressure when a patient with excess weight is advised from the health care provider to change his lifestyle. A healthy lifestyle with reduction in body weight, reduction in caloric intake, increased fruit and vegetables consumption and reduced salt intake concomitant with an increase in physical exercise can reduce body weight and hypertension in overweight and obese patients, but not all obese are able to reduce their blood pressure and lose weight without treatment and special dietary care. Moreover, most obese people lose weight for a small period and then they regain all the weight that they have lost or even worse, they increase their weight more than before starting a diet. Newly-approved weight loss drugs have variable actions on high blood pressure. Liraglutide and phentermine/topiramate seem to reduce hypertension, while after the bupropion/naltrexone or lorcaserin use trials reported a rise in blood pressure.
Conclusion: Reduction in body weight with treatment is not always associated with reduction in obesity induced hypertension. Weight loss treatments that exhibit sympathomimetic or adrenergic actions should be used with care and for short periods of time.
Keywords: Obesity, hypertension, obesity-induced hypertension, anti-obesity drugs, liraglutide, bupropion/naltrexone, phentermine / topiramate, lorcaserin.
Current Pharmaceutical Design
Title:Obesity-Induced Hypertension: New Insights
Volume: 23 Issue: 31
Author(s): Christina Antza, Stella Stabouli, Michalis Natsis, Ioannis Doundoulakis and Vasilios Kotsis*
Affiliation:
- 3rd Department of Internal Medicine, Hypertension-24h ABPM ESH Center of Excellence, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki,Greece
Keywords: Obesity, hypertension, obesity-induced hypertension, anti-obesity drugs, liraglutide, bupropion/naltrexone, phentermine / topiramate, lorcaserin.
Abstract: Background: New insights on the relationship between weight loss and hypertension and the role of the newly approved anti-obesity drugs on hypertension will be discussed
Methods: Weight loss is a major factor to reduce blood pressure when a patient with excess weight is advised from the health care provider to change his lifestyle. A healthy lifestyle with reduction in body weight, reduction in caloric intake, increased fruit and vegetables consumption and reduced salt intake concomitant with an increase in physical exercise can reduce body weight and hypertension in overweight and obese patients, but not all obese are able to reduce their blood pressure and lose weight without treatment and special dietary care. Moreover, most obese people lose weight for a small period and then they regain all the weight that they have lost or even worse, they increase their weight more than before starting a diet. Newly-approved weight loss drugs have variable actions on high blood pressure. Liraglutide and phentermine/topiramate seem to reduce hypertension, while after the bupropion/naltrexone or lorcaserin use trials reported a rise in blood pressure.
Conclusion: Reduction in body weight with treatment is not always associated with reduction in obesity induced hypertension. Weight loss treatments that exhibit sympathomimetic or adrenergic actions should be used with care and for short periods of time.
Export Options
About this article
Cite this article as:
Antza Christina , Stabouli Stella , Natsis Michalis , Doundoulakis Ioannis and Kotsis Vasilios*, Obesity-Induced Hypertension: New Insights, Current Pharmaceutical Design 2017; 23 (31) . https://dx.doi.org/10.2174/1381612823666170608083343
DOI https://dx.doi.org/10.2174/1381612823666170608083343 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Parathyroid Hormone and Ischemic Cerebrovascular Event
Endocrine, Metabolic & Immune Disorders - Drug Targets The Assessment of Platelet Activation in Antiplatelet Drug Development
Current Medicinal Chemistry Mild Carbohydrate Intolerance in Pregnancy
Current Diabetes Reviews Bryothamnion seaforthii Lectin Relaxes Vascular Smooth Muscle: Involvement of Endothelium and NO Synthase
Protein & Peptide Letters Statins in Stroke Prevention: Present and Future
Current Pharmaceutical Design Pulmonary Hypertension and Lung Transplantation
Current Hypertension Reviews Salt-Sensitive Hypertension: Perspectives on Intrarenal Mechanisms
Current Hypertension Reviews Preface [Hot Topic:Pharmacology of Weight Regulation Guest (Editor: Jason C.G. Halford)]
Current Drug Targets Nutrapharmacology of Tocotrienols for Metabolic Syndrome
Current Pharmaceutical Design Low-Dose Mercury Exposure in Early Life: Relevance of Thimerosal to Fetuses, Newborns and Infants
Current Medicinal Chemistry The Supremacy of Synergism: A Comparison of Anticancer Activity of Rhizome Extract of Bistorta Amplexicaulis and Gallic Acid in Cancer Cell Lines and Primary Cells
Current Nutraceuticals Microsponge Embedded Tablets for Sustained Delivery of Nifedipine
Pharmaceutical Nanotechnology Drug Repositioning Through Network Pharmacology
Current Topics in Medicinal Chemistry Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma
Current Medicinal Chemistry The Role of Antioxidants in the Prevention of Cadmium-Induced Endothelial Dysfunction
Current Pharmaceutical Design Pulmonary Vascular Function in Insulin Resistance and Diabetes
Current Vascular Pharmacology A synopsis on the linkage between age-related dementias and vascular disorders
CNS & Neurological Disorders - Drug Targets Chickpea (Cicer arietinum L.) Lectin Exhibit Inhibition of ACE-I, α-amylase and α-glucosidase Activity
Protein & Peptide Letters Phytochemical, Pharmacological Activities and Ayurvedic Significances of Magical Plant <i>Mimosa pudica Linn</i>
Mini-Reviews in Organic Chemistry Incretins and Preservation of Endothelial Function
Cardiovascular & Hematological Agents in Medicinal Chemistry